SCHEMBL187915

SCHEMBL187915

[c]1ccc2c(c1)ccn2CCN1CCCC1

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 17/20 0.46
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6754238 0.81 NOS3 (0.44) CDK4CCND1NOS3NOS1NOS2
SCHEMBL3990185 0.77 CDK4 (0.71) HTR7CDK4CCND1
SCHEMBL694594 0.77 CDK4 (0.41) CDK4CCND1
SCHEMBL29780338 0.77 CDK4 (0.71) HTR7CDK4CCND1
SCHEMBL1450476 0.77 CDK4 (0.41) CDK4CCND1
SCHEMBL27382849 0.77 CDK4 (0.41) CDK4CCND1
SCHEMBL1451528 0.76 HTR7 (0.39) HTR7CDK4CCND1NOS3NOS1
SCHEMBL12543448 0.76 CDK4 (0.69) HTR7CDK4CCND1
SCHEMBL16719844 0.74 CDK4 (0.44) CDK4CCND1
SCHEMBL5814894 0.74 CDK4 (0.44) CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed
US-20090036474-A1 Quinazoline derivatives for use against cancer PLE PATRICK 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036474-A1 Quinazoline derivatives for use against cancer AQP3, AQP1, F12 HTR7 606/4885CDK4 66/4885CCND1 6/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK HTR7 4068/4885CDK4 52/4885CCND1 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.